ADX-2191 was designated as an orphan medicinal product by the European Commission for the treatment of retinal detachment, according to a press release from Aldeyra Therapeutics.
Treatments that qualify for this designation are intended to treat a life-threatening or chronically debilitating condition that affects five or fewer people in 10,000 throughout the European Union.
The investigational therapy, an intravitreal formulation of methotrexate, which is in clinical development in the United States for the prevention of proliferative vitreoretinopathy, previously received orphan drug status
Uncategorized